“We are proud to bring this innovative treatment to Japanese patients through the partnership with GC Pharma,” said Yoshikazu Nakamura, Representative Director at Clinigen K.K.. “Hunter Syndrome is a complex disease with unmet medical need. We earnestly hope that this product provides significant benefit to patients in Japan.”
“We are delighted to further enhance the value of Hunterase through this partnership,” said Eun Chul Huh, Ph.D., President at GC Pharma. “Our efforts to make substantial differences in the lives of those with Hunter syndrome in all markets will continue by providing new treatment environments and opportunities.
About Hunter syndrome
Hunter syndrome (Mucopolysaccharidosis type II) is an inherited lysosomal storage disease that occurs primarily in boys. It causes an enzyme deficiency that interferes with the body’s ability to break down certain complex sugars, resulting in serious skeletal, tissue, neurological and multi-organ complications and, ultimately, death. It occurs in approximately 1.3 out of 100,000 male newborns. There is no cure. The standard treatments are enzyme replacement therapy (ERT) or palliative care.
About GC Pharma
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is one of the largest protein products manufacturers in the world and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company’s registered, legal name.
About Clinigen K.K.
Clinigen K.K. is a wholly owned subsidiary of Clinigen Group plc, global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines, based in Burton Upon Trent, UK. Clinigen K.K. focuses on the development and commercialization of medicines for rare diseases.
In collaboration with Link Healthcare K.K. (Clinigen Group), Clinigen K.K. provides ethical and timely access to licensed and unlicensed medicines to improve the quality of people’s lives in Japan.
For more on Clinigen K.K. please visit www.clinigen.co.jp
SOURCE GC Pharma
Download: Analysis on Edge Data Center Market characteristics https://www.technavio.com/talk-to-us?report=IRTNTR44689 The rising demand for video streaming services is one of the major factors propelling market growth. However, factors
CINCINNATI, 25. Juni 2021 /PRNewswire/ — Standard Textile Co. und Küçükçalık geben heute bekannt, dass sie ein Joint Venture-Abkommen geschlossen haben. Die Joint Venture-Vereinbarung bringt
Renault Group and STMicroelectronics enter strategic cooperation on power electronics Renault Group selects STMicroelectronics as key innovation partner, securing the supply of electric and hybrid
Renault Group et STMicroelectronics annoncent leur coopération stratégique dans l’électronique de puissance Renault Group choisit STMicroelectronics comme partenaire clé en matière d’innovation, sécurisant l’approvisionnement et
PRESS RELEASE25 June 2021 Renault Group and STMicroelectronics enter strategic cooperation on power electronics Renault Group selects STMicroelectronics as key innovation partner, securing the supply
COMMUNIQUE DE PRESSE 25 juin 2021 Renault Group et STMicroelectronics annoncent leur coopération stratégique dans l’électronique de puissance Renault Group choisit STMicroelectronics comme partenaire clé